Abbott's MitraClip. (Abbott)

Abbott Laboratories’ experimental device to repair leaky heart valves continues to show promise in patients two years after they have been treated, new research published in the New England Journal of Medicine today shows.

The MitraClip device, which is currently being review by the U.S. Food and Drug Administration for possible approval, is considered an important development for heart patients with mitral regurgitation because serious cases require open-heart surgery to repair their valves. It could be on the U.S. market by the end of this year. Get the full story »